Differences in the expression of apoptotic proteins in Burkitt's lymphoma cell lines:: Potential models for screening apoptosis-inducing agents

被引:13
作者
Doucet, JP
Hussain, A
Al-Rasheed, M
Gaidano, G
Gutiérrez, M
Magrath, I
Bhatia, K
机构
[1] King Faisal Specialist Hosp & Res Ctr, KFNCCC&R, Riyadh 11211, Saudi Arabia
[2] Amadeo Avogadro Univ Eastern Piedmont, Dept Med Sci, Novara, Italy
[3] Int Network Canc Treatment & Res, Brussels, Belgium
关键词
Bcl-2; IAP; MAP-kinase; caspases; non-Hodgkin's lymphoma; apoptosis;
D O I
10.1080/10428190310001595713
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mammalian cells undergo programmed cell death by orchestrated interactions involving multiple independent pathways. At least one of them, the p53-dependent pathway is commonly compromised in Burkitt's lymphoma (BL) cell lines. Differences in the integrity of this pathway in various BL cell lines have made them useful experimental models in understanding response to standard or novel antitumor drugs vis-a-vis the p53 pathway. Non-p53-dependent loss of apoptotic regulation also contributes to the genesis and/or progression of lymphomas and it is possible that BL cell lines also represent these models. We have characterized the expression of multiple apoptotic proteins in a panel of BL cell lines and describe cell lines with loss of cIAP1, cIAP2, Bax, Bak, Bcl-Xs and p38 MAP-kinase. This data should make this panel of cell lines a useful screening system for testing novel apoptotic inducers.
引用
收藏
页码:357 / 362
页数:6
相关论文
共 32 条
[1]   A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J].
Ambrosini, G ;
Adida, C ;
Altieri, DC .
NATURE MEDICINE, 1997, 3 (08) :917-921
[2]   Death receptors: Signaling and modulation [J].
Ashkenazi, A ;
Dixit, VM .
SCIENCE, 1998, 281 (5381) :1305-1308
[3]   MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain [J].
Bae, J ;
Leo, CP ;
Hsu, SY ;
Hsueh, AJW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (33) :25255-25261
[4]   Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs [J].
Baell, JB ;
Huang, DCS .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (5-6) :851-863
[5]   Activation and activities of the p53 tumour suppressor protein [J].
Bálint, É ;
Vousden, KH .
BRITISH JOURNAL OF CANCER, 2001, 85 (12) :1813-1823
[6]  
BHATIA KG, 1992, CANCER RES, V52, P4273
[7]   The role of MAPK pathways in the action of chemotherapeutic drugs [J].
Boldt, S ;
Weidle, UH ;
Kolch, W .
CARCINOGENESIS, 2002, 23 (11) :1831-1838
[8]   Chemotherapy: targeting the mitochondrial cell death pathway [J].
Debatin, KM ;
Poncet, D ;
Kroemer, G .
ONCOGENE, 2002, 21 (57) :8786-8803
[9]   p53 alterations in human leukemia-lymphoma cell lines:: in vitro artifact or prerequisite for cell immortalization? [J].
Drexler, HG ;
Fombonne, S ;
Matsuo, Y ;
Hu, ZB ;
Hamaguchi, H ;
Uphoff, CC .
LEUKEMIA, 2000, 14 (01) :198-206
[10]  
Eggert A, 2001, CANCER RES, V61, P1314